progress in the treatment of tp53 mutated aml
Published 3 years ago • 2.5K plays • Length 8:14Download video MP4
Download video MP3
Similar videos
-
3:19
an overview of novel treatment approaches in tp53-mutated aml
-
1:26
updates in the treatment landscape of p53-mutated aml/mds
-
1:57
the benefit of allogeneic transplantation in patients with tp53-mutated aml
-
1:27
treatment options for patients with tp53-mutated aml
-
2:24
the challenges of treating tp53-mutated aml and mds
-
2:23
improving treatment for patients with tp53-mutated myeloid malignancies
-
1:33
the current guidelines and therapies for tp53-mutated mds and aml
-
6:32
a phase i trial of dsp-5336, a novel menin inhibitor, in the treatment of aml
-
23:26
yadira soto-feliciano: "mechanisms of transcriptional regulation by chromatin adaptor proteins"
-
21:38
drawing the line: the rationale behind blood tube collection order
-
2:22
the need for novel agents to treat patients with mcl who have relapsed after targeted therapy
-
0:44
predictors of poor response to azacitidine, venetoclax, and magrolimab in tp53-mutated aml
-
1:53
challenges in treating patients with tp53-mutated aml and future outlooks
-
1:28
the role of allogeneic transplantation in patients with aml in the frontline setting
-
2:27
addressing the unmet needs for patients with tp53-mutated aml
-
0:44
unmet needs in aml: tp53 mutations and maintenance therapy
-
1:13
the challenges of treating patients with mpns who possess a tp53 mutation
-
1:59
depth of molecular response in patients with tp53m mds & aml treated with magrolimab and azacitidine
-
0:58
options available to patients with tp53-mutated mds beyond stem cell transplantation
-
5:16
an analysis of tp53 mutation in aml and hr-mds
-
1:00
proof of principle to progress treatments
-
0:41
promising agents in aml: menin inhibitors & magrolimab in tp53-mutated aml